This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Parkinson disease (PD) has been strongly associated with systemic defects in mitochondrial function. The best characterized of these is probably reduced activity of complex I of the electron transport chain, which was first reported more than 25 years ago,1 after the discovery of the pro-parkinsonian toxin, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), and its mechanism of action: inhibition of complex I.2 Proof-of-concept that a systemic impairment of complex I can reproduce the selective nigrostriatal degeneration and Lewy pathology of PD came from the rotenone model of PD in rats in 2000.3 Shortly thereafter, it became clear that certain autosomal recessive forms of PD are caused by mutations in genes that affect mitochondrial function or quality control, such as parkin and PINK1. Moreover, both parkin and PINK1 mutations are associated with a loss of complex I activity.4,5
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 846
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2G2019S carriers and in vivo
Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2
Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium
Etiology of Parkinson’s disease